{"id":"https://openalex.org/W2465358907","doi":null,"title":"Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis.","display_name":"Clinical benefit of cetuximab and prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer: a single institution analysis.","publication_year":2014,"publication_date":"2014-01-01","ids":{"openalex":"https://openalex.org/W2465358907","mag":"2465358907","pmid":"https://pubmed.ncbi.nlm.nih.gov/24659647"},"language":"en","primary_location":{"id":"pmid:24659647","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24659647","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069700792","display_name":"Ana Cvetanovi\u0107","orcid":"https://orcid.org/0000-0002-4113-9274","observed_orcids":["https://orcid.org/0000-0002-4113-9274"]},"institutions":[{"id":"https://openalex.org/I152518017","display_name":"University of Nis","ror":"https://ror.org/00965bg92","country_code":"RS","type":"education","lineage":["https://openalex.org/I152518017"]}],"countries":["RS"],"is_corresponding":false,"raw_author_name":"Ana Cvetanovic","raw_affiliation_strings":["Clinic of Oncology Clinical Centre Nis, Faculty of Medicine, University of Nis, Nis, Serbia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic of Oncology Clinical Centre Nis, Faculty of Medicine, University of Nis, Nis, Serbia","institution_ids":["https://openalex.org/I152518017"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087450619","display_name":"Svetislav Vrbi\u0107","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Svetislav Vrbic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103646288","display_name":"Sladjana Filipovic","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sladjana Filipovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008582162","display_name":"Ivica Pej\u010di\u0107","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ivica Pejcic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025844960","display_name":"Du\u0161an Milenkovi\u0107","orcid":"https://orcid.org/0000-0002-7434-9534","observed_orcids":["https://orcid.org/0000-0002-7434-9534"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dusan Milenkovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023575586","display_name":"Nikola \u017divkovi\u0107","orcid":"https://orcid.org/0000-0002-3126-6683","observed_orcids":["https://orcid.org/0000-0002-3126-6683"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nikola Zivkovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083700388","display_name":"Milo\u0161 S. Kosti\u0107","orcid":"https://orcid.org/0000-0003-2839-3910","observed_orcids":["https://orcid.org/0000-0003-2839-3910","https://orcid.org/0000-0002-2009-1427"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Milos Kostic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5075080984","display_name":"Ivan Petkovi\u0107","orcid":"https://orcid.org/0000-0002-9110-4117","observed_orcids":["https://orcid.org/0000-0002-9110-4117"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ivan Petkovic","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4912,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.64854101,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"19","issue":"1","first_page":"83","last_page":"90"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.984000027179718},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.8429999947547913},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.652999997138977},{"id":"https://openalex.org/keywords/kras-wild-type","display_name":"KRAS wild-type","score":0.8859999775886536},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7760000228881836},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.7590000033378601},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9470000267028809},{"id":"https://openalex.org/keywords/egfr-inhibitors","display_name":"EGFR inhibitors","score":0.6320000290870667},{"id":"https://openalex.org/keywords/fluoropyrimidine-refractory-disease","display_name":"fluoropyrimidine-refractory disease","score":0.6549999713897705},{"id":"https://openalex.org/keywords/oxaliplatin-refractory-disease","display_name":"oxaliplatin-refractory disease","score":0.9900000095367432},{"id":"https://openalex.org/keywords/irinotecan-refractory-disease","display_name":"irinotecan-refractory disease","score":0.8460000157356262}],"concepts":[{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8805654048919678},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8488140106201172},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.8087456226348877},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6907612085342407},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.6377731561660767},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.620781660079956},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5462354421615601},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.544922947883606},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.5433287620544434},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4631691873073578},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3350803256034851}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011518","descriptor_name":"Proto-Oncogene Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D012868","descriptor_name":"Skin Abnormalities","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D012868","descriptor_name":"Skin Abnormalities","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016283","descriptor_name":"Proto-Oncogene Proteins p21(ras)","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018631","descriptor_name":"ras Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D064420","descriptor_name":"Drug-Related Side Effects and Adverse Reactions","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:24659647","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24659647","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","raw_type":"Journal Article"},{"id":"mag:2465358907","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24659647","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W45199982","https://openalex.org/W1999250974","https://openalex.org/W2002959795","https://openalex.org/W2045888711","https://openalex.org/W2047138772","https://openalex.org/W2049484790","https://openalex.org/W2069703793","https://openalex.org/W2071697240","https://openalex.org/W2082636029","https://openalex.org/W2091392373","https://openalex.org/W2095201384","https://openalex.org/W2098223440","https://openalex.org/W2100589633","https://openalex.org/W2106789440","https://openalex.org/W2115790682","https://openalex.org/W2120490763","https://openalex.org/W2121883222","https://openalex.org/W2131183275","https://openalex.org/W2134142320","https://openalex.org/W2142564546","https://openalex.org/W2144425748","https://openalex.org/W2145070131","https://openalex.org/W2146100972","https://openalex.org/W2155311724","https://openalex.org/W2156700619","https://openalex.org/W2158863975","https://openalex.org/W2164837623","https://openalex.org/W2165132869","https://openalex.org/W2168377135","https://openalex.org/W2171111432","https://openalex.org/W2245406219","https://openalex.org/W2892143481"],"related_works":["https://openalex.org/W2589383789","https://openalex.org/W2064054230","https://openalex.org/W2414046499","https://openalex.org/W3213690829","https://openalex.org/W2998802016","https://openalex.org/W2002178408","https://openalex.org/W2417759494","https://openalex.org/W2326450595","https://openalex.org/W2230454946","https://openalex.org/W2068937134"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"evaluate":[2],"the":[3,10,32,133,159,178,263],"clinical":[4,243],"benefits":[5],"of":[6,13,34,50,97,150,158,177,262,265],"cetuximab":[7],"(CTX)":[8],"and":[9,58,85,170,198,233,267],"prognostic":[11],"value":[12],"CTX-related":[14],"skin":[15,64,79,88,151,163,182,210,221],"toxicity":[16,65,73,80,89,152,164,183,211,222,259],"in":[17,155,167,173,186,192,199,249,253,270],"metastatic":[18],"colorectal":[19],"cancer":[20],"(mCRC)":[21],"patients.":[22,160,179],"METHODS:":[23],"Sixty":[24],"patients":[25,45,99,107,254],"were":[26,52],"tested":[27],"for":[28],"KRAS":[29,43],"mutation":[30],"at":[31],"Department":[33],"Oncology,":[35],"Clinical":[36],"Centre":[37],"Nis.":[38],"We":[39],"assessed":[40],"34":[41],"wild-type":[42],"mCRC":[44],"treated":[46],"with":[47,214,225,251,255,272],"CTX.":[48],"All":[49],"them":[51],"refractory":[53],"to":[54,67,218,227],"prior":[55],"fluoropyrimidine,":[56],"oxaliplatin":[57],"irinotecan-based":[59],"regimens.":[60],"The":[61,189,204],"maximum":[62],"grade":[63,208,223],"according":[66],"treatment":[68,219],"cycle":[69],"was":[70,74,130,138,145,153,165,184,195,212,260,269,274],"analyzed.":[71],"Skin":[72,258],"grouped":[75],"into":[76],"clinically":[77,86,171],"non-relevant":[78,162],"(grade":[81,90],"0-1:":[82],"Group":[83,92,193,200],"1)":[84],"relevant":[87,172],"2-4:":[91],"2).":[93],"RESULTS:":[94],"Ten":[95],"out":[96],"33":[98],"(30.30%)":[100],"achieved":[101,122],"partial":[102],"response":[103,124,127,217,266],"(PR).":[104],"Eight":[105],"additional":[106],"(24.24%)":[108],"showed":[109,206],"stable":[110],"disease":[111,117,134],"(SD),":[112],"whereas":[113,132],"15":[114],"(45.45%)":[115],"had":[116],"progression":[118,141],"(PD).":[119],"No":[120],"patient":[121],"complete":[123],"(CR).":[125],"Overall":[126],"rate":[128,136],"(ORR)":[129],"30.30%,":[131],"control":[135],"(DCR)":[137],"54.54%.The":[139],"median":[140],"free":[142],"survival":[143],"(PFS)":[144],"14":[146],"weeks.":[147],"Some":[148],"degree":[149],"observed":[154,166],"79.41%":[156],"(27/34)":[157],"Clinically":[161],"50%":[168],"(17/34),":[169],"50":[174],"%":[175],"(17/34)":[176],"Grade":[180],"4":[181],"documented":[185],"1":[187,194],"patient.":[188],"mean":[190],"PFS":[191],"12.65\u00b15.59":[196],"weeks":[197],"2":[201],"22.82\u00b112.16":[202],"(p<0.05).":[203],"results":[205],"that":[207],"2-4":[209],"associated":[213],"significantly":[215],"better":[216],"than":[220],"0-1,":[224],"regard":[226],"ORR":[228],"(80.00":[229],"vs":[230,237],"20.00%;":[231],"p<0.05)":[232],"DCR":[234],"(":[235],"66.66":[236],"33.33%;":[238],"p<0.05).":[239],"CONCLUSION:":[240],"Cetuximab":[241],"has":[242],"benefit":[244],"when":[245],"given":[246],"alone":[247],"or":[248],"combination":[250],"irinotecan":[252],"irinotecan-refractory":[256],"CRC.":[257],"one":[261],"predictors":[264],"it":[268],"line":[271],"what":[273],"expected.":[275]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-07-22T00:00:00"}